Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
1.770
+0.060 (+3.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Esperion Theraptc
< Previous
1
2
3
Next >
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12
July 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
July 24, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
July 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
June 28, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
May 14, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
May 08, 2024
Via
AB Newswire
Esperion Reports First Quarter 2024 Financial Results
May 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming May Investor Conferences
April 29, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report First Quarter 2024 Financial Results on May 7
April 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
April 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
April 01, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
March 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
March 22, 2024
From
Esperion Therapeutics
Via
Business Wire
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
March 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
March 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
February 13, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
February 01, 2024
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
January 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
January 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Proposed Public Offering of Common Stock
January 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
January 03, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.